Sexually transmitted infections: challenges ahead

The Lancet Infectious Diseases

Volumn 17, Issue 8, 2017, Pages e235-e279

  Unemo, Magnus ^a   Bradshaw, Catriona S ^b,c   Hocking, Jane S ^d   de Vries, Henry J C ^e,f   Francis, Suzanna C ^g   Mabey, David ^g   Marrazzo, Jeanne M ^h   Sonder, Gerard J B ^e,f   Schwebke, Jane R ^h   Hoornenborg, Elske ^e   Peeling, Rosanna W ^g   Philip, Susan S ⁱ   Low, Nicola ^j   Fairley, Christopher K ^b,c  

^a Örebro University   (Sweden)

^b MONASH UNIVERSITY   (Australia)

^c MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

ⁱ SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^j UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACORAFLOXACIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT; BACTERIAL VACCINE; CARBAPENEM DERIVATIVE; CHLAMYDIA VACCINE; DALBAVANCIN; DELAFLOXACIN; DNA TOPOISOMERASE INHIBITOR; EDP 322; EPETRABOROLE; ERAVACYCLINE; GEPOTIDACIN; GYRASE INHIBITOR; JNJ Q 2; LEFAMULIN; MACROLIDE; MODITHROMYCIN; MUT 056399; PLEUROMUTILIN; QUINOLONE DERIVATIVE; REDX 05931; SITAFLOXACIN; SM 295291; SM 369926; SOLITHROMYCIN; UNCLASSIFIED DRUG; VT 12 008911; VXC 486; WQ 3810; ZOLIFLODACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIOPHAGE; BIOFILM; CASE MANAGEMENT; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DISEASE ASSOCIATION; DRUG REPOSITIONING; FEMALE; GENITAL SYSTEM DISEASE; GLOBAL DISEASE BURDEN; GONORRHEA; GYNECOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LOWEST INCOME GROUP; MALE; MEN WHO HAVE SEX WITH MEN; MIDDLE INCOME COUNTRY; MONOTHERAPY; MORBIDITY; NEISSERIA GONORRHOEAE; OBSERVATIONAL STUDY; PELVIC INFLAMMATORY DISEASE; POINT OF CARE TESTING; POST EXPOSURE PROPHYLAXIS; PREEXPOSURE PROPHYLAXIS; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SCREENING TEST; SEXUAL TRANSMISSION; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; TRICHOMONIASIS; VACCINATION; VAGINA FLORA; VAGINITIS; CHEMOPROPHYLAXIS; COMMUNICABLE DISEASE CONTROL; DIAGNOSTIC TEST; DISEASE MANAGEMENT; DISEASE TRANSMISSION; GLOBAL HEALTH; POINT OF CARE SYSTEM; PREVENTION AND CONTROL; PROCEDURES; SEXUALLY TRANSMITTED DISEASES;

CHEMOPREVENTION; COMMUNICABLE DISEASE CONTROL; DIAGNOSTIC TESTS, ROUTINE; DISEASE MANAGEMENT; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, BACTERIAL; GLOBAL HEALTH; HUMANS; INCIDENCE; POINT-OF-CARE SYSTEMS; SEXUALLY TRANSMITTED DISEASES;

EID: 85022040487     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30310-9     Document Type: Review

References (486)

1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1545–1602.
2. Newman, L, Rowley, J, Vander Hoorn, S, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One, 10, 2015, e0143304.
3. Unemo, M, Jensen, JS, Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium. Nat Rev Urol 14 (2017), 139–152.
4. Holmes, KK, Sparling, PF, Stamm, WE, et al. Sexually transmitted diseases, 2008, McGraw-Hill, New York.
5. Galvin, SR, Cohen, MS, The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2 (2004), 33–42.
6. Low, N, Broutet, N, Adu-Sarkodie, Y, Barton, P, Hossain, M, Hawkes, S, Global control of sexually transmitted infections. Lancet 368 (2006), 2001–2016.
7. Wu, D, Hawkes, S, Buse, K, Prevention of mother-to-child transmission of syphilis and HIV in China: what drives political prioritization and what can this tell us about promoting dual elimination?. Int J Gynaecol Obstet 130:suppl 1 (2015), S32–S36.
8. Fee, E, Sin versus science: venereal disease in twentieth-century Baltimore. Fee, E, Fox, DM, (eds.) AIDS: the burdens of history, 1988, University of California Press, Berkeley and Los Angeles, 121–146.
9. Haggerty, CL, Gottlieb, SL, Taylor, BD, Low, N, Xu, F, Ness, RB, Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis 201:suppl 2 (2010), S134–S155.
10. Scholes, D, Stergachis, A, Heidrich, FE, Andrilla, H, Holmes, KK, Stamm, WE, Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 334 (1996), 1362–1366.
11. Hocking, JS, Screening for chlamydia: does it work, results from ACCEPt. Sex Transm Infect, 91, 2015, PL03.2 (abstr).
12. Fifer, H, Natarajan, U, Jones, L, et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med 374 (2016), 2504–2506.
13. Gottlieb, SL, Johnston, C, Future prospects for new vaccines against sexually transmitted infections. Curr Opin Infect Dis 30 (2017), 77–86.
14. Fethers, KA, Fairley, CK, Hocking, JS, Gurrin, LC, Bradshaw, CS, Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis 47 (2008), 1426–1435.
15. Liu, CM, Hungate, BA, Tobian, AA, et al. Penile microbiota and female partner bacterial vaginosis in Rakai, Uganda. mBio, 6, 2015, e00589.
16. Brotman, RM, Klebanoff, MA, Nansel, TR, et al. Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J Infect Dis 202 (2010), 1907–1915.
17. Cohen, CR, Lingappa, JR, Baeten, JM, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med, 9, 2012, e1001251.
18. Bradshaw, CS, Vodstrcil, LA, Hocking, JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis 56 (2013), 777–786.
19. Peeling, RW, Holmes, KK, Mabey, D, Ronald, A, Rapid tests for sexually transmitted infections (STIs): the way forward. Sex Transm Infect 82:suppl 5 (2006), v1–v6.
20. Eaton, LA, Kalichman, S, Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 4 (2007), 165–172.
21. Jensen, JS, Bradshaw, C, Management of Mycoplasma genitalium infections—can we hit a moving target?. BMC Infect Dis, 15, 2015, 343.
22. Jensen, JS, Mycoplasma genitalium: yet another challenging STI. Lancet Infect Dis, 2017 published online July 9, 2017. http://dx.doi.org/10.1016/S1473-3099(17)30364-X.
23. Chow, EP, Danielewski, JA, Fehler, G, et al. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis 15 (2015), 1314–1323.
24. Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice (The Red Book), 8th edn., 2012, Royal Australian College of General Practitioners, Melbourne.
25. Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections. http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/index-eng.php, 2010 (accessed May 13, 2017).
26. Public Health England. National chlamydia screening programme standards, 2014, Public Health England, London.
27. van den Broek, IV, Sfetcu, O, van der Sande, MA, et al. Changes in chlamydia control activities in Europe between 2007 and 2012: a cross-national survey. Eur J Public Health 26 (2016), 382–388.
28. Workowski, KA, Bolan, GA, the Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 64 (2015), 1–137.
29. Sutton, TL, Martinko, T, Hale, S, Fairchok, MP, Prevalence and high rate of asymptomatic infection of Chlamydia trachomatis in male college Reserve Officer Training Corps cadets. Sex Transm Dis 30 (2003), 901–904.
30. Peipert, JF, Clinical practice. Genital chlamydial infections. N Engl J Med 349 (2003), 2424–2430.
31. Hocking, JS, Guy, R, Walker, J, Tabrizi, SN, Advances in sampling and screening for chlamydia. Future Microbiol 8 (2013), 367–386.
32. ECDC. Guidance on chlamydia control in Europe—2015, 2016, European Centre for Disease Prevention and Control, Stockholm.
33. Dowdle, WR, The principles of disease elimination and eradication. Bull World Health Organ 76:suppl 2 (1998), 22–25.
34. WHO. Global health sector strategy on sexually transmitted infections 2016–2021, 2016, World Health Organization, Geneva.
35. Redmond, SM, Alexander-Kisslig, K, Woodhall, SC, et al. Genital chlamydia prevalence in Europe and non-European high income countries: systematic review and meta-analysis. PLoS One, 10, 2015, e0115753.
36. Mimiaga, MJ, Helms, DJ, Reisner, SL, et al. Gonococcal, chlamydia, and syphilis infection positivity among MSM attending a large primary care clinic, Boston, 2003 to 2004. Sex Transm Dis 36 (2009), 507–511.
37. van Liere, GA, Hoebe, CJ, Dukers-Muijrers, NH, Evaluation of the anatomical site distribution of chlamydia and gonorrhoea in men who have sex with men and in high-risk women by routine testing: cross-sectional study revealing missed opportunities for treatment strategies. Sex Transm Infect 90 (2014), 58–60.
38. Lewis, D, Newton, DC, Guy, RJ, et al. The prevalence of Chlamydia trachomatis infection in Australia: a systematic review and meta-analysis. BMC Infect Dis, 12, 2012, 113.
39. Goulet, V, de Barbeyrac, B, Raherison, S, et al. Prevalence of Chlamydia trachomatis: results from the first national population-based survey in France. Sex Transm Infect 86 (2010), 263–270.
40. Hocking, JS, Willis, J, Tabrizi, S, Fairley, CK, Garland, SM, Hellard, M, A chlamydia prevalence survey of young women living in Melbourne, Victoria. Sex Health 3 (2006), 235–240.
41. Klavs, I, Rodrigues, LC, Wellings, K, Kese, D, Hayes, R, Prevalence of genital Chlamydia trachomatis infection in the general population of Slovenia: serious gaps in control. Sex Transm Infect 80 (2004), 121–123.
42. van Bergen, J, Götz, HM, Richardus, JH, et al. Prevalence of urogenital Chlamydia trachomatis increases significantly with level of urbanisation and suggests targeted screening approaches: results from the first national population based study in the Netherlands. Sex Transm Infect 81 (2005), 17–23.
43. Kløvstad, H, Grjibovski, A, Aavitsland, P, Population based study of genital Chlamydia trachomatis prevalence and associated factors in Norway: a cross sectional study. BMC Infect Dis, 12, 2012, 150.
44. Datta, SD, Torrone, E, Kruszon-Moran, D, et al. Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999–2008. Sex Transm Dis 39 (2012), 92–96.
45. Sonnenberg, P, Clifton, S, Beddows, S, et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 382 (2013), 1795–1806.
46. Torrone, E, Papp, J, Weinstock, H, the Centers for Disease Control and Prevention (CDC). Prevalence of Chlamydia trachomatis genital infection among persons aged 14–39 years—United States, 2007–2012. MMWR Morb Mortal Wkly Rep 63 (2014), 834–838.
47. Božičević, I, Grgić, I, Židovec-Lepej, S, et al. Urine-based testing for Chlamydia trachomatis among young adults in a population-based survey in Croatia: feasibility and prevalence. BMC Public Health, 11, 2011, 230.
48. Franceschi, S, Smith, JS, van den Brule, A, et al. Cervical infection with Chlamydia trachomatis and Neisseria gonorrhoeae in women from ten areas in four continents. A cross-sectional study. Sex Transm Dis 34 (2007), 563–569.
49. Joyee, AG, Thyagarajan, SP, Rajendran, P, et al. Chlamydia trachomatis genital infection in apparently healthy adult population of Tamil Nadu, India: a population-based study. Int J STD AIDS 15 (2004), 51–55.
50. Parish, WL, Laumann, EO, Cohen, MS, et al. Population-based study of chlamydial infection in China: a hidden epidemic. JAMA 289 (2003), 1265–1273.
51. Passey, M, Mgone, CS, Lupiwa, S, et al. Community based study of sexually transmitted diseases in rural women in the highlands of Papua New Guinea: prevalence and risk factors. Sex Transm Infect 74 (1998), 120–127.
52. Crichton, J, Hickman, M, Campbell, R, Batista-Ferrer, H, Macleod, J, Socioeconomic factors and other sources of variation in the prevalence of genital chlamydia infections: a systematic review and meta-analysis. BMC Public Health, 15, 2015, 729.
53. Op de Coul, EL, Götz, HM, van Bergen, JE, et al. Who participates in the Dutch chlamydia screening? A study on demographic and behavioral correlates of participation and positivity. Sex Transm Dis 39 (2012), 97–103.
54. Vallely, A, Page, A, Dias, S, et al. The prevalence of sexually transmitted infections in Papua New Guinea: a systematic review and meta-analysis. PLoS One, 5, 2010, e15586.
55. World Health Organization Western Pacific Region. Second generation surveillance surveys of HIV, other STIs and risk behaviours in 6 Pacific Island countries: 2004–2005, 2006, World Health Organization, Geneva.
56. Moodley, D, Moodley, P, Sebitloane, M, et al. High prevalence and incidence of asymptomatic sexually transmitted infections during pregnancy and postdelivery in KwaZulu Natal, South Africa. Sex Transm Dis 42 (2015), 43–47.
57. Bingham, AL, Kavanagh, AM, Fairley, CK, Keogh, LA, Bentley, RJ, Hocking, JS, Income inequality and Neisseria gonorrhoeae notifications in females: a country-level analysis. Sex Health 11 (2014), 556–560.
58. WHO. Global health estimates 2014 summary tables: DALY by cause, age and sex, by WHO region, 2000–2012, 2014, World Health Organization, Geneva.
59. Bender, N, Herrmann, B, Andersen, B, et al. Chlamydia infection, pelvic inflammatory disease, ectopic pregnancy and infertility: cross-national study. Sex Transm Infect 87 (2011), 601–608.
60. Goller, JL, De Livera, AM, Fairley, CK, et al. Characteristics of pelvic inflammatory disease where no sexually transmitted infection is identified: a cross-sectional analysis of routinely collected sexual health clinic data. Sex Transm Infect 93 (2017), 68–70.
61. Gottlieb, SL, Martin, DH, Xu, F, Byrne, GI, Brunham, RC, Summary: the natural history and immunobiology of Chlamydia trachomatis genital infection and implications for chlamydia control. J Infect Dis 201:suppl 2 (2010), S190–S204.
62. Darville, T, Hiltke, TJ, Pathogenesis of genital tract disease due to Chlamydia trachomatis. J Infect Dis 201:suppl 2 (2010), S114–S125.
63. Geisler, WM, Lensing, SY, Press, CG, Hook, EW 3rd, Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection. J Infect Dis 207 (2013), 1850–1856.
64. Brunham, RC, Pourbohloul, B, Mak, S, White, R, Rekart, ML, The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis 192 (2005), 1836–1844.
65. Brunham, RC, Rekart, ML, The arrested immunity hypothesis and the epidemiology of chlamydia control. Sex Transm Dis 35 (2008), 53–54.
66. Walker, J, Tabrizi, SN, Fairley, CK, et al. Chlamydia trachomatis incidence and re-infection among young women—behavioural and microbiological characteristics. PLoS One, 7, 2012, e37778.
67. LaMontagne, D, Baster, K, Emmett, L, et al. Incidence and reinfection rates of genital chlamydia infection among women aged 16 to 24 years attending general practice, family planning and genitourinary medicine clinics in England: a prospective cohort study by the Chlamydia Recall Study Advisory Group. Sex Transm Infect 83 (2007), 292–303.
68. van Valkengoed, IG, Morré, SA, van den Brule, AJ, Meijer, CJ, Bouter, LM, Boeke, AJ, Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes—implications for cost-effectiveness analyses. Int J Epidemiol 33 (2004), 416–425.
69. Wallace, LA, Scoular, A, Hart, G, Reid, M, Wilson, P, Goldberg, DJ, What is the excess risk of infertility in women after genital chlamydia infection? A systematic review of the evidence. Sex Transm Infect 84 (2008), 171–175.
70. Land, JA, Van Bergen, JE, Morré, SA, Postma, MJ, Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Hum Reprod Update 16 (2010), 189–204.
71. Risser, WL, Risser, JM, The incidence of pelvic inflammatory disease in untreated women infected with Chlamydia trachomatis: a structured review. Int J STD AIDS 18 (2007), 727–731.
72. Price, MJ, Ades, AE, De Angelis, D, et al. Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model. Am J Epidemiol 178 (2013), 484–492.
73. Kavanagh, K, Wallace, LA, Robertson, C, Wilson, P, Scoular, A, Estimation of the risk of tubal factor infertility associated with genital chlamydial infection in women: a statistical modelling study. Int J Epidemiol 42 (2013), 493–503.
74. Price, MJ, Ades, AE, Soldan, K, et al. The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis. Health Technol Assess 20 (2016), 1–250.
75. Davies, B, Turner, KM, Frølund, M, et al. Risk of reproductive complications following chlamydia testing: a population-based retrospective cohort study in Denmark. Lancet Infect Dis 16 (2016), 1057–1064.
76. Davies, B, Ward, H, Leung, S, et al. Heterogeneity in risk of pelvic inflammatory diseases after chlamydia infection: a population-based study in Manitoba, Canada. J Infect Dis 210:suppl 2 (2014), S549–S555.
77. Bakken, IJ, Skjeldestad, FE, Lydersen, S, Nordbø, SA, Births and ectopic pregnancies in a large cohort of women tested for Chlamydia trachomatis. Sex Transm Dis 34 (2007), 739–743.
78. Smith, KJ, Cook, RL, Roberts, MS, Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: influence on the cost-effectiveness of different screening intervals. Value Health 10 (2007), 358–366.
79. Herzog, SA, Althaus, CL, Heijne, JC, et al. Timing of progression from Chlamydia trachomatis infection to pelvic inflammatory disease: a mathematical modelling study. BMC Infect Dis, 12, 2012, 187.
80. Oakeshott, P, Kerry, S, Aghaizu, A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ, 340, 2010, c1642.
81. Rours, GI, Duijts, L, Moll, HA, et al. Chlamydia trachomatis infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. Eur J Epidemiol 26 (2011), 493–502.
82. Rours, GI, Hammerschlag, MR, Van Doornum, GJ, et al. Chlamydia trachomatis respiratory infection in Dutch infants. Arch Dis Child 94 (2009), 705–707.
83. Trojian, TH, Lishnak, TS, Heiman, D, Epididymitis and orchitis: an overview. Am Fam Physician 79 (2009), 583–587.
84. Gimenes, F, Souza, RP, Bento, JC, et al. Male infertility: a public health issue caused by sexually transmitted pathogens. Nat Rev Urol 11 (2014), 672–687.
85. Eley, A, Pacey, AA, Galdiero, M, Galdiero, M, Galdiero, F, Can Chlamydia trachomatis directly damage your sperm?. Lancet Infect Dis 5 (2005), 53–57.
86. Khosropour, CM, Broad, JM, Scholes, D, Saint-Johnson, J, Manhart, LE, Golden, MR, Estimating chlamydia screening coverage: a comparison of self-report and health care effectiveness data and information set measures. Sex Transm Dis 41 (2014), 665–670.
87. Public Health England. Sexually transmitted infections and chlamydia screening in England, 2015. Health Protection Report, 10, 2016.
88. Kirby Institute. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2015, 2015, Kirby Institute, Sydney.
89. ECDC. Chlamydia control in Europe: literature review, 2014, European Centre for Disease Prevention and Control, Stockholm.
90. Low, N, Redmond, S, Uusküla, A, et al. Screening for genital chlamydia infection. Cochrane Database Syst Rev, 9, 2016 CD010866.
91. Low, N, Screening programmes for chlamydial infection: when will we ever learn?. BMJ 334 (2007), 725–728.
92. Low, N, Geisler, W, Stevenson, J, Hook, E III, Chlamydia control: a comparative review from the USA and UK. Aral, S, Fenton, K, Lipshutz, J, (eds.) The new public health and STD/HIV prevention, 2013, Springer, New York, 401–429.
93. Andersen, B, van Valkengoed, I, Sokolowski, I, Møller, JK, Østergaard, L, Olesen, F, Impact of intensified testing for urogenital Chlamydia trachomatis infections: a randomised study with 9-year follow-up. Sex Transm Infect 87 (2011), 156–161.
94. Ostergaard, L, Andersen, B, Møller, JK, Olesen, F, Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study. Clin Infect Dis 31 (2000), 951–957.
95. Hocking, JS, Low, N, Guy, R, et al. Australian Chlamydia Control Effectiveness Pilot (ACCEPt): a cluster randomised controlled trial of chlamydia testing in general practice (ACTRN1260000297022). Lancet, 2013 Protocol 12PRT/9010 http://www.thelancet.com/protocol-reviews/12PRT-9101 (accessed May 13, 2017).
96. van den Broek, IV, van Bergen, JE, Brouwers, EE, et al. Effectiveness of yearly, register based screening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation. BMJ, 345, 2012, e4316.
97. García, PJ, Holmes, KK, Cárcamo, CP, et al. Prevention of sexually transmitted infections in urban communities (Peru PREVEN): a multicomponent community-randomised controlled trial. Lancet 379 (2012), 1120–1128.
98. Martin, DH, Eschenbach, DA, Cotch, MF, et al. Double-blind placebo-controlled treatment trial of Chlamydia trachomatis endocervical infections in pregnant women. Infect Dis Obstet Gynecol 5 (1997), 10–17.
99. Gray, RH, Wabwire-Mangen, F, Kigozi, G, et al. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Am J Obstet Gynecol 185 (2001), 1209–1217.
100. Ong, KJ, Soldan, K, Jit, M, Dunbar, JK, Woodhall, SC, Chlamydia sequelae cost estimates used in current economic evaluations: does one-size-fit-all?. Sex Transm Infect 93 (2017), 18–24.
101. Sheringham, J, Simms, I, Riha, J, et al. Will chlamydia screening reach young people in deprived areas in England? Baseline analysis of the English National Chlamydia Screening Programme delivery in 2008. Sex Transm Dis 38 (2011), 677–684.
102. Health Protection Agency. Primary Care Trust (PCT) and Strategic Health Authority (SHA) specific tables 2011/2012. 2012.
103. Tao, G, Hoover, KW, Leichliter, JS, Peterman, TA, Kent, CK, Self-reported chlamydia testing rates of sexually active women aged 15–25 years in the United States, 2006–2008. Sex Transm Dis 39 (2012), 605–607.
104. Hoover, KW, Leichliter, JS, Torrone, EA, Loosier, PS, Gift, TL, Tao, G, the Centers for Disease Control and Prevention (CDC). Chlamydia screening among females aged 15–21 years—multiple data sources, United States, 1999–2010. MMWR Suppl 63 (2014), 80–88.
105. Batteiger, BE, Tu, W, Ofner, S, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 201 (2010), 42–51.
106. Althaus, CL, Heijne, JC, Roellin, A, Low, N, Transmission dynamics of Chlamydia trachomatis affect the impact of screening programmes. Epidemics 2 (2010), 123–131.
107. Regan, DG, Wilson, DP, Hocking, JS, Coverage is the key for effective screening of Chlamydia trachomatis in Australia. J Infect Dis 198 (2008), 349–358.
108. Rank, RG, Yeruva, L, Hidden in plain sight: chlamydial gastrointestinal infection and its relevance to persistence in human genital infection. Infect Immun 82 (2014), 1362–1371.
109. Musil, K, Currie, M, Sherley, M, Martin, S, Rectal chlamydia infection in women at high risk of chlamydia attending Canberra Sexual Health Centre. Int J STD AIDS 27 (2016), 526–530.
110. Danby, CS, Cosentino, LA, Rabe, LK, et al. Patterns of extragenital chlamydia and gonorrhea in women and men who have sex with men reporting a history of receptive anal intercourse. Sex Transm Dis 43 (2016), 105–109.
111. Kintner, J, Lajoie, D, Hall, J, Whittimore, J, Schoborg, RV, Commonly prescribed β-lactam antibiotics induce C. trachomatis persistence/stress in culture at physiologically relevant concentrations. Front Cell Infect Microbiol, 4, 2014, 44.
112. Hogan, RJ, Mathews, SA, Mukhopadhyay, S, Summersgill, JT, Timms, P, Chlamydial persistence: beyond the biphasic paradigm. Infect Immun 72 (2004), 1843–1855.
113. Wyrick, PB, Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis 201:suppl 2 (2010), S88–S95.
114. Phillips-Campbell, R, Kintner, J, Schoborg, RV, Induction of the Chlamydia muridarum stress/persistence response increases azithromycin treatment failure in a murine model of infection. Antimicrob Agents Chemother 58 (2014), 1782–1784.
115. Reveneau, N, Crane, DD, Fischer, E, Caldwell, HD, Bactericidal activity of first-choice antibiotics against gamma interferon-induced persistent infection of human epithelial cells by Chlamydia trachomatis. Antimicrob Agents Chemother 49 (2005), 1787–1793.
116. Sutton, MY, Sternberg, M, Zaidi, A, St Louis, ME, Markowitz, LE, Trends in pelvic inflammatory disease hospital discharges and ambulatory visits, United States, 1985–2001. Sex Transm Dis 32 (2005), 778–784.
117. Chen, MY, Pan, Y, Britt, H, Donovan, B, Trends in clinical encounters for pelvic inflammatory disease and epididymitis in a national sample of Australian general practices. Int J STD AIDS 17 (2006), 384–386.
118. Scholes, D, Satterwhite, CLP, Yu, O, Fine, D, Weinstock, H, Berman, S, Long-term trends in Chlamydia trachomatis infections and related outcomes in a US managed care population. Sex Transm Dis 39 (2012), 81–88.
119. French, CE, Hughes, G, Nicholson, A, et al. Estimation of the rate of pelvic inflammatory disease diagnoses: trends in England, 2000–2008. Sex Transm Dis 38 (2011), 158–162.
120. Moore, MS, Golden, MR, Scholes, D, Kerani, RP, Assessing trends in chlamydia positivity and gonorrhea incidence and their associations with the incidence of pelvic inflammatory disease and ectopic pregnancy in Washington state, 1988–2010. Sex Transm Dis 43 (2016), 2–8.
121. Rekart, ML, Gilbert, M, Meza, R, et al. Chlamydia public health programs and the epidemiology of pelvic inflammatory disease and ectopic pregnancy. J Infect Dis 207 (2013), 30–38.
122. Moss, NJ, Ahrens, K, Kent, CK, Klausner, JD, The decline in clinical sequelae of genital Chlamydia trachomatis infection supports current control strategies. J Infect Dis 193 (2006), 1336–1338.
123. Organisation for Economic Co-operation and Development (OECD). Hospital discharge rates (indicator). http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_PROC, 2016 (accessed Aug 30, 2016).
124. Nicoll, A, Hughes, G, Donnelly, M, et al. Assessing the impact of national anti-HIV sexual health campaigns: trends in the transmission of HIV and other sexually transmitted infections in England. Sex Transm Infect 77 (2001), 242–247.
125. Morgan, J, Bell, A, The highs and lows of opportunistic chlamydia testing: uptake and detection in Waikato, New Zealand. Sex Transm Infect 85 (2009), 452–454.
126. Kong, FYS, Guy, RJ, Hocking, JS, et al. Australian general practitioner chlamydia testing rates among young people. Med J Aust 194 (2011), 249–252.
127. Marks, M, Bottomley, C, Tome, H, et al. Mass drug administration of azithromycin for trachoma reduces the prevalence of genital Chlamydia trachomatis infection in the Solomon Islands. Sex Transm Infect 92 (2016), 261–265.
128. Handsfield, HH, Questioning azithromycin for chlamydial infection. Sex Transm Dis 38 (2011), 1028–1029.
129. Hocking, JS, Kong, FY, Timms, P, Huston, WM, Tabrizi, SN, Treatment of rectal chlamydia infection may be more complicated than we originally thought. J Antimicrob Chemother 70 (2015), 961–964.
130. Horner, PJ, Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy. Sex Transm Infect 88 (2012), 154–156.
131. Horner, P, Saunders, J, Should azithromycin 1 g be abandoned as a treatment for bacterial STIs? The case for and against. Sex Transm Infect 93 (2017), 85–87.
132. Kong, FY, Tabrizi, SN, Law, M, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 59 (2014), 193–205.
133. Kong, FY, Tabrizi, SN, Fairley, CK, et al. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. J Antimicrob Chemother 70 (2015), 1290–1297.
134. WHO. Guidelines for the management of sexually transmitted infections, 2004, World Health Organization, Geneva.
135. Chen, XS, Yin, YP, Wei, WH, et al. High prevalence of azithromycin resistance to Treponema pallidum in geographically different areas in China. Clin Microbiol Infect 19 (2013), 975–979.
136. Read, P, Tagg, KA, Jeoffreys, N, Guy, RJ, Gilbert, GL, Donovan, B, Treponema pallidum strain types and association with macrolide resistance in Sydney, Australia: new TP0548 gene types identified. J Clin Microbiol 54 (2016), 2172–2174.
137. Chisholm, SA, Wilson, J, Alexander, S, et al. An outbreak of high-level azithromycin resistant Neisseria gonorrhoeae in England. Sex Transm Infect 92 (2016), 365–367.
138. Lau, A, Bradshaw, CS, Lewis, D, et al. The efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta-analysis. Clin Infect Dis 61 (2015), 1389–1399.
139. Ferreira, A, Young, T, Mathews, C, Zunza, M, Low, N, Strategies for partner notification for sexually transmitted infections, including HIV. Cochrane Database Syst Rev, 10, 2013 CD002843.
140. Althaus, CL, Turner, KM, Mercer, CH, et al. Effectiveness and cost-effectiveness of traditional and new partner notification technologies for curable sexually transmitted infections: observational study, systematic reviews and mathematical modelling. Health Technol Assess 18 (2014), 1–100.
141. Estcourt, CS, Sutcliffe, LJ, Copas, A, et al. Developing and testing accelerated partner therapy for partner notification for people with genital Chlamydia trachomatis diagnosed in primary care: a pilot randomised controlled trial. Sex Transm Infect 91 (2015), 548–554.
142. Pavlin, NL, Parker, RM, Piggin, AK, et al. Better than nothing? Patient-delivered partner therapy and partner notification for chlamydia: the views of Australian general practitioners. BMC Infect Dis, 10, 2010, 274.
143. Australasian Sexual Health Alliance. Australian STI management guidelines for use in primary care. Chlamydia. http://www.sti.guidelines.org.au/sexually-transmissible-infections/chlamydia#management, 2014 (accessed May 13, 2017).
144. Lanjouw, E, Ouburg, S, de Vries, HJ, Stary, A, Radcliffe, K, Unemo, M, 2015 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS 27 (2016), 333–348.
145. Heijne, JC, Herzog, SA, Althaus, CL, Tao, G, Kent, CK, Low, N, Insights into the timing of repeated testing after treatment for Chlamydia trachomatis: data and modelling study. Sex Transm Infect 89 (2013), 57–62.
146. Kampman, C, Koedijk, F, Driessen-Hulshof, H, Hautvast, J, van den Broek, I, Retesting young STI clinic visitors with urogenital Chlamydia trachomatis infection in the Netherlands; response to a text message reminder and reinfection rates: a prospective study with historical controls. Sex Transm Infect 92 (2016), 124–129.
147. Smith, KS, Hocking, JS, Chen, MY, et al. Dual intervention to increase chlamydia retesting: a randomized controlled trial in three populations. Am J Prev Med 49 (2015), 1–11.
148. Pai, NP, Vadnais, C, Denkinger, C, Engel, N, Pai, M, Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med, 9, 2012, e1001306.
149. Wingrove, I, McOwan, A, Nwokolo, N, Whitlock, G, Diagnostics within the clinic to test for gonorrhoea and chlamydia reduces the time to treatment: a service evaluation. Sex Transm Infect, 90, 2014, 474.
150. Hafner, LM, Wilson, DP, Timms, P, Development status and future prospects for a vaccine against Chlamydia trachomatis infection. Vaccine 32 (2014), 1563–1571.
151. Gottlieb, SL, Deal, CD, Giersing, B, et al. The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps. Vaccine 34 (2016), 2939–2947.
152. Darville, T, the Pelvic Inflammatory Disease Workshop Proceedings Committee. Pelvic inflammatory disease: identifying research gaps—proceedings of a workshop sponsored by Department of Health and Human Services/National Institutes of Health/National Institute of Allergy and Infectious Diseases, November 3–4, 2011. Sex Transm Dis 40 (2013), 761–767.
153. Unemo, M, Del Rio, C, Shafer, WM, Antimicrobial resistance expressed by Neisseria gonorrhoeae: a major global public health problem in the 21st century. Microbiol Spectr, 4, 2016.
154. Unemo, M, Shafer, WM, Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 27 (2014), 587–613.
155. WHO, Department of Reproductive Health and Research. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae, 2012, World Health Organization, Geneva, 1–36.
156. Tapsall, JW, Ndowa, F, Lewis, DA, Unemo, M, Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 7 (2009), 821–834.
157. Unemo, M, Nicholas, RA, Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 7 (2012), 1401–1422.
158. Lewis, DA, Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant Neisseria gonorrhoeae strains?. Sex Transm Infect 91 (2015), 234–237.
159. Unemo, M, Current and future antimicrobial treatment of gonorrhoea—the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis, 15, 2015, 364.
160. De Silva, D, Peters, J, Cole, K, et al. Whole-genome sequencing to determine transmission of Neisseria gonorrhoeae: an observational study. Lancet Infect Dis 16 (2016), 1295–1303.
161. Cámara, J, Serra, J, Ayats, J, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 67 (2012), 1858–1860.
162. Ohnishi, M, Golparian, D, Shimuta, K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 55 (2011), 3538–3545.
163. Unemo, M, Golparian, D, Nicholas, R, Ohnishi, M, Gallay, A, Sednaoui, P, High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 56 (2012), 1273–1280.
164. Deguchi, T, Yasuda, M, Hatazaki, K, et al. New clinical strain of Neisseria gonorrhoeae with decreased susceptibility to ceftriaxone, Japan. Emerg Infect Dis 22 (2016), 142–144.
165. Lahra, MM, Ryder, N, Whiley, DM, A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia. N Engl J Med 371 (2014), 1850–1851.
166. Nakayama, S, Shimuta, K, Furubayashi, K, Kawahata, T, Unemo, M, Ohnishi, M, New ceftriaxone- and multidrug-resistant Neisseria gonorrhoeae strain with a novel mosaic penA gene isolated in Japan. Antimicrob Agents Chemother 60 (2016), 4339–4341.
167. Gianecini, R, Oviedo, C, Stafforini, G, Galarza, P, Neisseria gonorrhoeae resistant to ceftriaxone and cefixime, Argentina. Emerg Infect Dis 22 (2016), 1139–1141.
168. AWMF Register. Nr 059/004—S2k-leitlinie: gonorrhoe bei erwachsenen und adoleszenten aktueller stand. 2013: 1–31 (in German).
169. Australasian Sexual Health Alliance. Australian STI management guidelines for use in primary care. Gonorrhoea. http://www.sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea#management (accessed May 10, 2017).
170. Bignell, C, Fitzgerald, M the Guideline Development Group, the British Association for Sexual Health and HIV UK. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 22 (2011), 541–547.
171. Bignell, C, Unemo, M, the European STI Guidelines Editorial Board. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 24 (2013), 85–92.
172. Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections. Gonococcal infections chapter 5. http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-5-6-eng.php, 2013 (accessed May 10, 2017).
173. WHO, Department of Reproductive Health and Research. WHO guidelines for the treatment of Neisseria gonorrhoeae. http://www.ncbi.nlm.nih.gov/pubmed/27512795, 2016 (accessed May 10, 2017).
174. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. Strategies and laboratory methods for strengthening surveillance of sexually transmitted infections, 2012, World Health Organization, Geneva.
175. Centers for Disease Control. Antibiotic-resistant strains of Neisseria gonorrhoeae. Policy guidelines for detection, management, and control. MMWR Suppl 36 (1987), 1S–18S.
176. Moran, JS, Levine, WC, Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 20:suppl 1 (1995), S47–S65.
177. Ison, CA, Deal, C, Unemo, M, Current and future treatment options for gonorrhoea. Sex Transm Infect 89:suppl 4 (2013), iv52–iv56.
178. Japanese Society of Sexually Transmitted Infection. Gonococcal infection. Sexually transmitted infections, diagnosis and treatment guidelines 2011. Jpn J Sex Transm Dis 22:suppl 1 (2011), 52–59.
179. Ito, S, Yasuda, M, Hatazaki, K, et al. Microbiological efficacy and tolerability of a single-dose regimen of 1 g of ceftriaxone in men with gonococcal urethritis. J Antimicrob Chemother 71 (2016), 2559–2562.
180. Tapsall, JW, Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sex Transm Infect 85 (2009), 256–258.
181. Unemo, M, Shipitsyna, E, Domeika, M, the Eastern European Sexual and Reproductive Health (EE SRH) Network Antimicrobial Resistance Group. Recommended antimicrobial treatment of uncomplicated gonorrhoea in 2009 in 11 East European countries: implementation of a Neisseria gonorrhoeae antimicrobial susceptibility programme in this region is crucial. Sex Transm Infect 86 (2010), 442–444.
182. Chisholm, SA, Mouton, JW, Lewis, DA, Nichols, T, Ison, CA, Livermore, DM, Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?. J Antimicrob Chemother 65 (2010), 2141–2148.
183. Singh, AE, Gratrix, J, Martin, I, et al. Gonorrhea treatment failures with oral and injectable expanded spectrum cephalosporin monotherapy vs dual therapy at 4 Canadian sexually transmitted infection clinics, 2010–2013. Sex Transm Dis 42 (2015), 331–336.
184. Rice, LB, Will use of combination cephalosporin/azithromycin therapy forestall resistance to cephalosporins in Neisseria gonorrhoeae?. Sex Transm Infect 91 (2015), 238–240.
185. Lee, H, Unemo, M, Kim, HJ, Seo, Y, Lee, K, Chong, Y, Emergence of decreased susceptibility and resistance to extended-spectrum cephalosporins in Neisseria gonorrhoeae in Korea. J Antimicrob Chemother 70 (2015), 2536–2542.
186. Moran, JS, Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important?. Sex Transm Dis 22 (1995), 39–47.
187. Kirkcaldy, RD, Weinstock, HS, Moore, PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 59 (2014), 1083–1091.
188. Dowell, D, Kirkcaldy, RD, Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Sex Transm Infect 88 (2012), 589–594.
189. Hathorn, E, Dhasmana, D, Duley, L, Ross, JD, The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review. Syst Rev, 3, 2014, 104.
190. Hauser, C, Hirzberger, L, Unemo, M, Furrer, H, Endimiani, A, In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother 59 (2015), 1605–1611.
191. Goire, N, Lahra, MM, Chen, M, et al. Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance. Nat Rev Microbiol 12 (2014), 223–229.
192. Low, N, Unemo, M, Molecular tests for the detection of antimicrobial resistant Neisseria gonorrhoeae: when, where, and how to use?. Curr Opin Infect Dis 29 (2016), 45–51.
193. Allan-Blitz, LT, Humphries, RM, Hemarajata, P, et al. Implementation of a rapid genotypic assay to promote targeted ciprofloxacin therapy of Neisseria gonorrhoeae in a large health system. Clin Infect Dis 64 (2017), 1268–1270.
194. Allan-Blitz, LT, Klausner, JD, Codon 91 Gyrase A testing is necessary and sufficient to predict ciprofloxacin susceptibility in Neisseria gonorrhoeae. J Infect Dis, 215, 2017, 491.
195. Bruhn, DF, Waidyarachchi, SL, Madhura, DB, et al. Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections. Sci Transl Med, 7, 2015, 288ra75.
196. Savage, VJ, Charrier, C, Salisbury, AM, et al. Efficacy of a novel tricyclic topoisomerase inhibitor in a murine model of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 60 (2016), 5592–5594.
197. Savage, VJ, Charrier, C, Salisbury, AM, et al. Biological profiling of novel tricyclic inhibitors of bacterial DNA gyrase and topoisomerase IV. J Antimicrob Chemother 71 (2016), 1905–1913.
198. Melinta Therapeutics. Melinta Therapeutics Ceases Phase 3 PROCEEDING Study—Company Notice. http://melinta.com/melinta-therapeutics-ceases-phase-3-proceeding-study (accessed May 5, 2017).
199. Alm, RA, Lahiri, SD, Kutschke, A, et al. Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 59 (2015), 1478–1486.
200. Basarab, GS, Kern, GH, McNulty, J, et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial type II topoisomerases. Sci Rep, 5, 2015, 11827.
201. Basarab GS, McNulty J, Gales S, et al. Non-clinical safety profile of a novel gyrase inhibitor for treatment of Neisseria gonorrhoeae infections. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology; Washington DC, USA; 2014. F-268 (abstr).
202. Biedenbach, DJ, Bouchillon, SK, Hackel, M, et al. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother 60 (2016), 1918–1923.
203. Foerster, S, Golparian, D, Jacobsson, S, et al. Genetic resistance determinants, in vitro time-kill curve analysis and pharmacodynamic functions for the novel topoisomerase II inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae. Front Microbiol, 6, 2015, 1377.
204. Golparian, D, Fernandes, P, Ohnishi, M, Jensen, JS, Unemo, M, In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?. Antimicrob Agents Chemother 56 (2012), 2739–2742.
205. Hook, EW 3rd, Golden, M, Jamieson, BD, et al. A phase 2 trial of oral solithromycin 1200 mg or 1000 mg as single-dose oral therapy for uncomplicated gonorrhea. Clin Infect Dis 61 (2015), 1043–1048.
206. Tiffany CA, Hossain M, McDonald M, Dumont EF. Safety and pharmacokinetics of repeat escalating oral doses of GSK2140944, a novel bacterial topoisomerase inhibitor. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology; Washington DC, USA; 2014. F-278 (abstr).
207. Huband, MD, Bradford, PA, Otterson, LG, et al. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria. Antimicrob Agents Chemother 59 (2015), 467–474.
208. Jacobsson, S, Golparian, D, Alm, RA, et al. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother 58 (2014), 5585–5588.
209. Lawrence K, O'Connor K, Atuah K, Matthews D, Gardner H. Safety and pharmacokinetics of single escalating oral doses of AZD0914: a novel spiropyrimidinetrione antibacterial agent. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology; Washington DC, USA; 2014. F-267 (abstr).
210. Llano-Sotelo, B, Dunkle, J, Klepacki, D, et al. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother 54 (2010), 4961–4970.
211. Negash, K, Andonian, C, Felgate, C, et al. The metabolism and disposition of GSK2140944 in healthy human subjects. Xenobiotica 46 (2016), 683–702.
212. Olsen, B, Pham, TL, Golparian, D, Johansson, E, Tran, HK, Unemo, M, Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011. BMC Infect Dis, 13, 2013, 40.
213. Papp, JR, Lawrence, K, Sharpe, S, Mueller, J, Kirkcaldy, RD, In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione. Int J Antimicrob Agents 48 (2016), 328–330.
214. Putnam, SD, Castanheira, M, Moet, GJ, Farrell, DJ, Jones, RN, CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagn Microbiol Infect Dis 66 (2010), 393–401.
215. Scangarella-Oman NE, Dixon P, Koeth LM, DiFranco-Fisher J, Miller LA. Analysis of agar dilution MIC testing methods and variables and in vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae. ASM Microbe 2016; Boston, USA; 2016.
216. Still, JG, Schranz, J, Degenhardt, TP, et al. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother 55 (2011), 1997–2003.
217. Su, XH, Wang, BX, Le, WJ, et al. Multidrug-resistant Neisseria gonorrhoeae isolates from Nanjing, China, are sensitive to killing by a novel DNA gyrase inhibitor, ETX0914 (AZD0914). Antimicrob Agents Chemother 60 (2015), 621–623.
218. Unemo, M, Ringlander, J, Wiggins, C, Fredlund, H, Jacobsson, S, Cole, M, High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014. Antimicrob Agents Chemother 59 (2015), 5220–5225.
219. Taylor SN, Marrazzo J, Batteiger BE, et al. A phase II trial of single-dose oral ETX0914 (AZD0914) for treatment of uncomplicated urogenital gonorrhea. 2016 STD Prevention Conference; Atlanta, USA; 2016. 5B5 (abstr).
220. Golparian, D, Shafer, WM, Ohnishi, M, Unemo, M, Importance of multidrug efflux pumps in the antimicrobial resistance property of clinical multidrug-resistant isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 58 (2014), 3556–3559.
221. Cempra. Cempra provides corporate update and reports fourth quarter and full year 2016 financial results. http://investor.cempra.com/releasedetail.cfm?ReleaseID=1014807, Feb 28, 2017 (accessed March 2, 2017).
222. Taneja, N, Kaur, H, Insights into newer antimicrobial agents against Gram-negative bacteria. Microbiol Insights 9 (2016), 9–19.
223. Demczuk, W, Lynch, T, Martin, I, et al. Whole-genome phylogenomic heterogeneity of Neisseria gonorrhoeae isolates with decreased cephalosporin susceptibility collected in Canada between 1989 and 2013. J Clin Microbiol 53 (2015), 191–200.
224. Demczuk, W, Martin, I, Peterson, S, et al. Genomic epidemiology and molecular resistance mechanisms of azithromycin-resistant Neisseria gonorrhoeae in Canada from 1997 to 2014. J Clin Microbiol 54 (2016), 1304–1313.
225. Grad, YH, Kirkcaldy, RD, Trees, D, et al. Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study. Lancet Infect Dis 14 (2014), 220–226.
226. Graham, RM, Doyle, CJ, Jennison, AV, Epidemiological typing of Neisseria gonorrhoeae and detection of markers associated with antimicrobial resistance directly from urine samples using next generation sequencing. Sex Transm Infect 93 (2017), 65–67.
227. Jacobsson, S, Golparian, D, Cole, M, et al. WGS analysis and molecular resistance mechanisms of azithromycin-resistant (MIC >2 mg/L) Neisseria gonorrhoeae isolates in Europe from 2009 to 2014. J Antimicrob Chemother 71 (2016), 3109–3116.
228. Unemo, M, Golparian, D, Sánchez-Busó, L, et al. The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. J Antimicrob Chemother 71 (2016), 3096–3108.
229. Gardner, HL, Dukes, CD, Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified non-specific vaginitis. Am J Obstet Gynecol 69 (1955), 962–976.
230. Potter, J, Should sexual partners of women with bacterial vaginosis receive treatment?. Br J Gen Pract 49 (1999), 913–918.
231. Amaya-Guio, J, Viveros-Carreño, DA, Sierra-Barrios, EM, Martinez-Velasquez, MY, Grillo-Ardila, CF, Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database Syst Rev, 10, 2016 CD011701.
232. Mehta, SD, Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sex Transm Dis 39 (2012), 822–830.
233. Fredricks, DN, Fiedler, TL, Marrazzo, JM, Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 353 (2005), 1899–1911.
234. Boskey, ER, Cone, RA, Whaley, KJ, Moench, TR, Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod 16 (2001), 1809–1813.
235. Aroutcheva, A, Gariti, D, Simon, M, et al. Defense factors of vaginal lactobacilli. Am J Obstet Gynecol 185 (2001), 375–379.
236. Swidsinski, A, Doerffel, Y, Loening-Baucke, V, et al. Gardnerella biofilm involves females and males and is transmitted sexually. Gynecol Obstet Invest 70 (2010), 256–263.
237. Swidsinski, A, Mendling, W, Loening-Baucke, V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 106 (2005), 1013–1023.
238. Bradshaw, CS, Walker, J, Fairley, CK, et al. Prevalent and incident bacterial vaginosis are associated with sexual and contraceptive behaviours in young Australian women. PLoS One, 8, 2013, e57688.
239. Allsworth, JE, Bacterial vaginosis—race and sexual transmission: issues of causation. Sex Transm Dis 37 (2010), 137–139.
240. Koumans, EH, Sternberg, M, Bruce, C, et al. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 34 (2007), 864–869.
241. Chico, RM, Mayaud, P, Ariti, C, Mabey, D, Ronsmans, C, Chandramohan, D, Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: a systematic review. JAMA 307 (2012), 2079–2086.
242. Bilardi, JE, Walker, S, Temple-Smith, M, et al. The burden of bacterial vaginosis: women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One, 8, 2013, e74378.
243. Bilardi, J, Walker, S, McNair, R, et al. Women's management of recurrent bacterial vaginosis and experiences of clinical care: a qualitative study. PLoS One, 11, 2016, e0151794.
244. Bilardi, J, Walker, S, Mooney-Somers, J, et al. Women's views and experiences of the triggers for onset of bacterial vaginosis and exacerbating factors associated with recurrence. PLoS One, 11, 2016, e0150272.
245. Peipert, JF, Lapane, KL, Allsworth, JE, Redding, CA, Blume, JD, Stein, MD, Bacterial vaginosis, race, and sexually transmitted infections: does race modify the association?. Sex Transm Dis 35 (2008), 363–367.
246. Myer, L, Kuhn, L, Stein, ZA, Wright, TC Jr, Denny, L, Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis 5 (2005), 786–794.
247. Cherpes, TL, Meyn, LA, Krohn, MA, Lurie, JG, Hillier, SL, Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis 37 (2003), 319–325.
248. Hay, PE, Lamont, RF, Taylor-Robinson, D, Morgan, DJ, Ison, C, Pearson, J, Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ 308 (1994), 295–298.
249. Hillier, SL, Nugent, RP, Eschenbach, DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. N Engl J Med 333 (1995), 1737–1742.
250. Koumans, EH, Markowitz, LE, Berman, SM, St Louis, ME, A public health approach to adverse outcomes of pregnancy associated with bacterial vaginosis. Int J Gynaecol Obstet 67:suppl 1 (1999), S29–S33.
251. Hawes, SE, Hillier, SL, Benedetti, J, et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis 174 (1996), 1058–1063.
252. Vaca, M, Guadalupe, I, Erazo, S, et al. High prevalence of bacterial vaginosis in adolescent girls in a tropical area of Ecuador. BJOG 117 (2010), 225–228.
253. Bump, RC, Buesching, WJ 3rd, Bacterial vaginosis in virginal and sexually active adolescent females: evidence against exclusive sexual transmission. Am J Obstet Gynecol 158 (1988), 935–939.
254. Yen, S, Shafer, MA, Moncada, J, Campbell, CJ, Flinn, SD, Boyer, CB, Bacterial vaginosis in sexually experienced and non-sexually experienced young women entering the military. Obstet Gynecol 102 (2003), 927–933.
255. Fethers, KA, Fairley, CK, Morton, A, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis 200 (2009), 1662–1670.
256. Schwebke, JR, Desmond, R, Risk factors for bacterial vaginosis in women at high risk for sexually transmitted diseases. Sex Transm Dis 32 (2005), 654–658.
257. Bradshaw, CS, Morton, AN, Hocking, J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 193 (2006), 1478–1486.
258. Sanchez, S, Garcia, PJ, Thomas, KK, Catlin, M, Holmes, KK, Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol 191 (2004), 1898–1906.
259. Schwebke, JR, Desmond, RA, A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis 44 (2007), 213–219.
260. Hellberg, D, Nilsson, S, Mårdh, PA, Bacterial vaginosis and smoking. Int J STD AIDS 11 (2000), 603–606.
261. Brotman, RM, He, X, Gajer, P, et al. Association between cigarette smoking and the vaginal microbiota: a pilot study. BMC Infect Dis, 14, 2014, 471.
262. Bradshaw, CS, Walker, SM, Vodstrcil, LA, et al. The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW Health Study. J Infect Dis 209 (2014), 1562–1572.
263. Bradshaw, CS, Morton, AN, Garland, SM, Morris, MB, Moss, LM, Fairley, CK, Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol 106 (2005), 105–114.
264. Ness, RB, Hillier, SL, Richter, HE, et al. Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. Obstet Gynecol, 100, 2002, 765.
265. Neggers, YH, Nansel, TR, Andrews, WW, et al. Dietary intake of selected nutrients affects bacterial vaginosis in women. J Nutr 137 (2007), 2128–2133.
266. Paul, K, Boutain, D, Manhart, L, Hitti, J, Racial disparity in bacterial vaginosis: the role of socioeconomic status, psychosocial stress, and neighborhood characteristics, and possible implications for preterm birth. Soc Sci Med 67 (2008), 824–833.
267. Berger, BJ, Kolton, S, Zenilman, JM, Cummings, MC, Feldman, J, McCormack, WM, Bacterial vaginosis in lesbians: a sexually transmitted disease. Clin Infect Dis 21 (1995), 1402–1405.
268. Evans, AL, Scally, AJ, Wellard, SJ, Wilson, JD, Prevalence of bacterial vaginosis in lesbians and heterosexual women in a community setting. Sex Transm Infect 83 (2007), 470–475.
269. Marrazzo, JM, Koutsky, LA, Eschenbach, DA, Agnew, K, Stine, K, Hillier, SL, Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis 185 (2002), 1307–1313.
270. Vodstrcil, LA, Walker, SM, Hocking, JS, et al. Incident bacterial vaginosis (BV) in women who have sex with women is associated with behaviors that suggest sexual transmission of BV. Clin Infect Dis 60 (2015), 1042–1053.
271. Marrazzo, JM, Thomas, KK, Agnew, K, Ringwood, K, Prevalence and risks for bacterial vaginosis in women who have sex with women. Sex Transm Dis 37 (2010), 335–339.
272. Marrazzo, JM, Thomas, KK, Fiedler, TL, Ringwood, K, Fredricks, DN, Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One, 5, 2010, e11139.
273. Marrazzo, JM, Antonio, M, Agnew, K, Hillier, SL, Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis 199 (2009), 680–683.
274. Liu, CM, Hungate, BA, Tobian, AA, et al. Male circumcision significantly reduces prevalence and load of genital anaerobic bacteria. MBio, 4, 2013, e00076.
275. Price, LB, Liu, CM, Johnson, KE, et al. The effects of circumcision on the penis microbiome. PLoS One, 5, 2010, e8422.
276. Zozaya, M, Ferris, MJ, Siren, JD, et al. Bacterial communities in penile skin, male urethra, and vaginas of heterosexual couples with and without bacterial vaginosis. Microbiome, 4, 2016, 16.
277. Eren, AM, Zozaya, M, Taylor, CM, Dowd, SE, Martin, DH, Ferris, MJ, Exploring the diversity of Gardnerella vaginalis in the genitourinary tract microbiota of monogamous couples through subtle nucleotide variation. PLoS One, 6, 2011, e26732.
278. Piot, P, Van Dyck, E, Peeters, M, Hale, J, Totten, PA, Holmes, KK, Biotypes of Gardnerella vaginalis. J Clin Microbiol 20 (1984), 677–679.
279. Holst, E, Reservoir of four organisms associated with bacterial vaginosis suggests lack of sexual transmission. J Clin Microbiol 28 (1990), 2035–2039.
280. Nelson, DE, Dong, Q, Van der Pol, B, et al. Bacterial communities of the coronal sulcus and distal urethra of adolescent males. PLoS One, 7, 2012, e36298.
281. Gray, RH, Kigozi, G, Serwadda, D, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol, 200, 2009, 42.
282. Swidsinski, A, Dörffel, Y, Loening-Baucke, V, et al. Desquamated epithelial cells covered with a polymicrobial biofilm typical for bacterial vaginosis are present in randomly selected cryopreserved donor semen. FEMS Immunol Med Microbiol 59 (2010), 399–404.
283. Swidsinski, A, Loening-Baucke, V, Mendling, W, et al. Infection through structured polymicrobial Gardnerella biofilms (StPM-GB). Histol Histopathol 29 (2014), 567–587.
284. Keane, FE, Thomas, BJ, Whitaker, L, Renton, A, Taylor-Robinson, D, An association between non-gonococcal urethritis and bacterial vaginosis and the implications for patients and their sexual partners. Genitourin Med 73 (1997), 373–377.
285. Bradshaw, CS, Tabrizi, SN, Read, TRH, et al. Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis 193 (2006), 336–345.
286. Manhart, LE, Khosropour, CM, Liu, C, et al. Bacterial vaginosis-associated bacteria in men: association of Leptotrichia/Sneathia spp. with nongonococcal urethritis. Sex Transm Dis 40 (2013), 944–949.
287. Burdge, DR, Bowie, WR, Chow, AW, Gardnerella vaginalis-associated balanoposthitis. Sex Transm Dis 13 (1986), 159–162.
288. Swedberg, J, Steiner, JF, Deiss, F, Steiner, S, Driggers, DA, Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis. JAMA 254 (1985), 1046–1049.
289. Colli, E, Landoni, M, Parazzini, F, Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial. Genitourin Med 73 (1997), 267–270.
290. Moi, H, Prevalence of bacterial vaginosis and its association with genital infections, inflammation, and contraceptive methods in women attending sexually transmitted disease and primary health clinics. Int J STD AIDS 1 (1990), 86–94.
291. Mengel, MB, Berg, AO, Weaver, CH, et al. The effectiveness of single-dose metronidazole therapy for patients and their partners with bacterial vaginosis. J Fam Pract 28 (1989), 163–171.
292. Vejtorp, M, Bollerup, AC, Vejtorp, L, et al. Bacterial vaginosis: a double-blind randomized trial of the effect of treatment of the sexual partner. Br J Obstet Gynaecol 95 (1988), 920–926.
293. Vutyavanich, T, Pongsuthirak, P, Vannareumol, P, Ruangsri, RA, Luangsook, P, A randomized double-blind trial of tinidazole treatment of the sexual partners of females with bacterial vaginosis. Obstet Gynecol 82 (1993), 550–554.
294. Kiliç, AO, Pavlova, SI, Alpay, S, Kiliç, SS, Tao, L, Comparative study of vaginal Lactobacillus phages isolated from women in the United States and Turkey: prevalence, morphology, host range, and DNA homology. Clin Diagn Lab Immunol 8 (2001), 31–39.
295. Pavlova, SI, Kiliç, AO, Mou, SM, Tao, L, Phage infection in vaginal lactobacilli: an in vitro study. Infect Dis Obstet Gynecol 5 (1997), 36–44.
296. Blackwell, AL, Vaginal bacterial phaginosis?. Sex Transm Infect 75 (1999), 352–353.
297. Koumans, EH, Markowitz, LE, Hogan, V, the CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis 35:suppl 2 (2002), S152–S172.
298. Oduyebo, OO, Anorlu, RI, Ogunsola, FT, The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev, 3, 2009 CD006055.
299. Hanson, JM, McGregor, JA, Hillier, SL, et al. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs oral therapy. J Reprod Med 45 (2000), 889–896.
300. Sobel, JD, Schmitt, C, Meriwether, C, Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin. J Infect Dis 167 (1993), 783–784.
301. Sobel, JD, Vaginitis. N Engl J Med 337 (1997), 1896–1903.
302. Marrazzo, JM, Thomas, KK, Fiedler, TL, Ringwood, K, Fredricks, DN, Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med 149 (2008), 20–28.
303. Bradshaw, CS, Brotman, RM, Making inroads into improving treatment of bacterial vaginosis—striving for long-term cure. BMC Infect Dis, 15, 2015, 292.
304. Beigi, RH, Austin, MN, Meyn, LA, Krohn, MA, Hillier, SL, Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 191 (2004), 1124–1129.
305. Austin, MN, Beigi, RH, Meyn, LA, Hillier, SL, Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J Clin Microbiol 43 (2005), 4492–4497.
306. McClelland, RS, Balkus, JE, Lee, J, et al. Randomized trial of periodic presumptive treatment with high-dose intravaginal metronidazole and miconazole to prevent vaginal infections in HIV-negative women. J Infect Dis 211 (2015), 1875–1882.
307. Sobel, JD, Ferris, D, Schwebke, J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 194 (2006), 1283–1289.
308. Bradshaw, CS, Sobel, JD, Current treatment of bacterial vaginosis-limitations and need for innovation. J Infect Dis 214:suppl 1 (2016), S14–S20.
309. Muzny, CA, Schwebke, JR, Biofilms: an underappreciated mechanism of treatment failure and recurrence in vaginal infections. Clin Infect Dis 61 (2015), 601–606.
310. Swidsinski, A, Dörffel, Y, Loening-Baucke, V, Schilling, J, Mendling, W, Response of Gardnerella vaginalis biofilm to 5 days of moxifloxacin treatment. FEMS Immunol Med Microbiol 61 (2011), 41–46.
311. Swidsinski, A, Mendling, W, Loening-Baucke, V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol, 198, 2008, 97.
312. Reichman, O, Akins, R, Sobel, JD, Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis 36 (2009), 732–734.
313. Swidsinski, A, Loening-Baucke, V, Swidsinski, S, Verstraelen, H, Polymicrobial Gardnerella biofilm resists repeated intravaginal antiseptic treatment in a subset of women with bacterial vaginosis: a preliminary report. Arch Gynecol Obstet 291 (2015), 605–609.
314. Hymes, SR, Randis, TM, Sun, TY, Ratner, AJ, DNase inhibits Gardnerella vaginalis biofilms in vitro and in vivo. J Infect Dis 207 (2013), 1491–1497.
315. Turovskiy, Y, Cheryian, T, Algburi, A, et al. Susceptibility of Gardnerella vaginalis biofilms to natural antimicrobials subtilosin, epsilon-poly-L-lysine, and lauramide arginine ethyl ester. Infect Dis Obstet Gynecol, 2012, 2012, 284762.
316. Eade, CR, Cole, AL, Diaz, C, et al. The anti-HIV microbicide candidate RC-101 inhibits pathogenic vaginal bacteria without harming endogenous flora or mucosa. Am J Reprod Immunol 69 (2013), 150–158.
317. Hooven, TA, Randis, TM, Hymes, SR, Rampersaud, R, Ratner, AJ, Retrocyclin inhibits Gardnerella vaginalis biofilm formation and toxin activity. J Antimicrob Chemother 67 (2012), 2870–2872.
318. Gottschick, C, Szafranski, SP, Kunze, B, et al. Screening of compounds against Gardnerella vaginalis biofilms. PLoS One, 11, 2016, e0154086.s.
319. Brackman, G, Coenye, T, Quorum sensing inhibitors as anti-biofilm agents. Curr Pharm Des 21 (2015), 5–11.
320. Deng, Y, Lim, A, Lee, J, et al. Diffusible signal factor (DSF) quorum sensing signal and structurally related molecules enhance the antimicrobial efficacy of antibiotics against some bacterial pathogens. BMC Microbiol, 14, 2014, 51.
321. Senok, AC, Verstraelen, H, Temmerman, M, Botta, GA, Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev, 4, 2009 CD006289.
322. Hemmerling, A, Harrison, W, Schroeder, A, et al. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis. Sex Transm Dis 36 (2009), 564–569.
323. Hemmerling, A, Harrison, W, Schroeder, A, et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis 37 (2010), 745–750.
324. Ngugi, BM, Hemmerling, A, Bukusi, EA, et al. Effects of bacterial vaginosis-associated bacteria and sexual intercourse on vaginal colonization with the probiotic Lactobacillus crispatus CTV-05. Sex Transm Dis 38 (2011), 1020–1027.
325. Stapleton, AE, Au-Yeung, M, Hooton, TM, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 52 (2011), 1212–1217.
326. Verstraelen, H, Verhelst, R, Roelens, K, Temmerman, M, Antiseptics and disinfectants for the treatment of bacterial vaginosis: a systematic review. BMC Infect Dis, 12, 2012, 148.
327. Wetmore, CM, Manhart, LE, Wasserheit, JN, Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future. Epidemiol Rev 32 (2010), 121–136.
328. Joseph Davey, DL, Shull, HI, Billings, JD, Wang, D, Adachi, K, Klausner, JD, Prevalence of curable sexually transmitted infections in pregnant women in low- and middle-income countries from 2010 to 2015: a systematic review. Sex Transm Dis 43 (2016), 450–458.
329. Wijesooriya, NS, Rochat, RW, Kamb, ML, et al. Global burden of maternal and congenital syphilis in 2008 and 2012: a health systems modelling study. Lancet Glob Health 4 (2016), e525–e533.
330. UNAIDS. On the fast-track to an AIDS free generation, 2016, Joint United Nations Programme on HIV/AIDS, Geneva.
331. Peeling, RW, Mabey, D, Fitzgerald, DW, Watson-Jones, D, Avoiding HIV and dying of syphilis. Lancet 364 (2004), 1561–1563.
332. Peeling, RW, Mabey, D, Celebrating the decline in syphilis in pregnancy: a sobering reminder of what's left to do. Lancet Glob Health 4 (2016), e503–e504.
333. Hawkes, S, Mabey, D, Mayaud, P, Partner notification for the control of sexually transmitted infections. BMJ 327 (2003), 633–634.
334. Steen, R, Chersich, M, Gerbase, A, et al. Periodic presumptive treatment of curable sexually transmitted infections among sex workers: a systematic review. AIDS 26 (2012), 437–445.
335. Murtagh, MM, The point-of-care diagnostic landscape for sexually transmitted infections (STIs). http://who.int/reproductivehealth/topics/rtis/pocts/en/ (accessed May 19, 2017).
336. Lush, L, Walt, G, Ogden, J, Transferring policies for treating sexually transmitted infections: what's wrong with global guidelines?. Health Policy Plan 18 (2003), 18–30.
337. Farley, TA, Cohen, DA, Elkins, W, Asymptomatic sexually transmitted diseases: the case for screening. Prev Med 36 (2003), 502–509.
338. Vickerman, P, Watts, C, Peeling, RW, Mabey, D, Alary, M, Modelling the cost effectiveness of rapid point of care diagnostic tests for the control of HIV and other sexually transmitted infections among female sex workers. Sex Transm Infect 82 (2006), 403–412.
339. Francis, SC, Ao, TT, Vanobberghen, FM, et al. Epidemiology of curable sexually transmitted infections among women at increased risk for HIV in northwestern Tanzania: inadequacy of syndromic management. PLoS One, 9, 2014, e101221.
340. Das, A, Pathni, AK, Narayanan, P, et al. High rates of reinfection and incidence of bacterial sexually transmitted infections in a cohort of female sex workers from two Indian cities: need for different STI control strategies?. Sex Transm Infect 89 (2013), 5–10.
341. Mlisana, K, Naicker, N, Werner, L, et al. Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis 206 (2012), 6–14.
342. Mayaud, P, ka-Gina, G, Cornelissen, J, et al. Validation of a WHO algorithm with risk assessment for the clinical management of vaginal discharge in Mwanza, Tanzania. Sex Transm Infect 74:suppl 1 (1998), S77–S84.
343. Iqbal, SM, Kaul, R, Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol 59 (2008), 44–54.
344. Peeling, RW, Mabey, D, Herring, A, Hook, EW 3rd, Why do we need quality-assured diagnostic tests for sexually transmitted infections?. Nat Rev Microbiol 4 (2006), 909–921.
345. Mayaud, P, Mabey, D, Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges. Sex Transm Infect 80 (2004), 174–182.
346. Alam, N, Chamot, E, Vermund, SH, Streatfield, K, Kristensen, S, Partner notification for sexually transmitted infections in developing countries: a systematic review. BMC Public Health, 10, 2010, 19.
347. WHO. Periodic presumptive treatment for sexually transmitted infections: experience from the field and recommendations for research, 2008, World Health Organization, Geneva.
348. Steen, R, Chersich, M, de Vlas, SJ, Periodic presumptive treatment of curable sexually transmitted infections among sex workers: recent experience with implementation. Curr Opin Infect Dis 25 (2012), 100–106.
349. Vickerman, P, Ndowa, F, O'Farrell, N, Steen, R, Alary, M, Delany-Moretlwe, S, Using mathematical modelling to estimate the impact of periodic presumptive treatment on the transmission of sexually transmitted infections and HIV among female sex workers. Sex Transm Infect 86 (2010), 163–168.
350. Watson-Jones, D, Gumodoka, B, Weiss, H, et al. Syphilis in pregnancy in Tanzania. The effectiveness of antenatal syphilis screening and single-dose benzathine penicillin treatment for the prevention of adverse pregnancy outcomes. J Infect Dis 186 (2002), 948–957.
351. Watson-Jones, D, Oliff, M, Terris-Prestholt, F, et al. Antenatal syphilis screening in sub-Saharan Africa: lessons learned from Tanzania. Trop Med Int Health 10 (2005), 934–943.
352. Hawkes, SJ, Matin, N, Broutet, N, Low, N, Effectiveness of interventions to improve screening for antenatal syphilis: a systematic review and meta-analysis. Lancet Infect Dis 11 (2011), 684–691.
353. Swartzendruber, A, Steiner, RJ, Adler, MR, Kamb, ML, Newman, LM, Introduction of rapid syphilis testing in antenatal care: a systematic review of the impact on HIV and syphilis testing uptake and coverage. Int J Gynaecol Obstet 130:suppl 1 (2015), S15–S21.
354. Medline, A, Joseph Davey, D, Klausner, JD, Lost opportunity to save newborn lives: variable national antenatal screening policies for Neisseria gonorrhoeae and Chlamydia trachomatis. Int J STD AIDS 28 (2017), 660–666.
355. Steen, R, Dallabettab, G, Sexually transmitted infection control with sex workers: regular screening and presumptive treatment augment efforts to reduce risk and vulnerability. Reprod Health Matters 11 (2003), 74–90.
356. Chersich, MF, Luchters, S, Ntaganira, I, et al. Priority interventions to reduce HIV transmission in sex work settings in sub-Saharan Africa and delivery of these services. J Int AIDS Soc, 16, 2013, 17980.
357. West, B, Walraven, G, Morison, L, Brouwers, J, Bailey, R, Performance of the rapid plasma reagin and the rapid syphilis screening tests in the diagnosis of syphilis in field conditions in rural Africa. Sex Transm Infect 78 (2002), 282–285.
358. Patel, A, Moodley, D, Moodley, J, An evaluation of on-site testing for syphilis. Trop Doct 31 (2001), 79–82.
359. Jenniskens, F, Obwaka, E, Kirisuah, S, et al. Syphilis control in pregnancy: decentralization of screening facilities to primary care level, a demonstration project in Nairobi, Kenya. Int J Gynaecol Obstet 48:suppl (1995), S121–S128.
360. Fonn, S, A blood-result turn-around time survey to improve congenital syphilis prevention in a rural area. S Afr Med J 86 (1996), 67–71.
361. Kettler, H, White, K, Hawkes, S, Mapping the landscape of diagnostics for sexually transmitted infections: key findings and recommendations, 2004, World Health Organization, Geneva.
362. Tucker, JD, Bien, CH, Peeling, RW, Point-of-care testing for sexually transmitted infections: recent advances and implications for disease control. Curr Opin Infect Dis 26 (2013), 73–79.
363. Gaydos, C, Hardick, J, Point of care diagnostics for sexually transmitted infections: perspectives and advances. Expert Rev Anti Infect Ther 12 (2014), 657–672.
364. Herbst de Cortina, S, Bristow, CC, Joseph Davey, D, Klausner, JD, A systematic review of point of care testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. Infect Dis Obstet Gynecol, 2016, 2016, 4386127.
365. Kelly, H, Coltart, CEM, Pant Pai, N, et al. Systematic reviews of point-of-care tests for the diagnosis of urogenital Chlamydia trachomatis infections. Sex Transm Infect, 2017 (in press).
366. Taylor, M, Gliddon, H, Kamb, M, Toskin, I, Wi, T, Peeling, RW, A systematic review and meta-analysis of studies evaluating the performance and operational characteristics of dual point-of-care tests for HIV and syphilis. Sex Transm Infect, 2017 (in press).
367. Gaydos, C, Klausner, JD, Pant Pai, N, Kelly, H, Coltart, CEM, Peeling, RW, Rapid and point-of-care tests for the diagnosis of Trichomonas vaginalis in women and men. Sex Transm Infect, 2017 (in press).
368. Badman, SG, Causer, LM, Guy, R, et al. A preliminary evaluation of a new GeneXpert (Gx) molecular point-of-care test for the detection of Trichomonas vaginalis. Sex Transm Infect 92 (2016), 350–352.
369. Pearce, DM, Styles, DN, Hardick, JP, Gaydos, CA, A new rapid molecular point-of-care assay for Trichomonas vaginalis: preliminary performance data. Sex Transm Infect 89 (2013), 495–497.
370. Guy, RJ, Causer, LM, Klausner, JD, et al. A review of studies evaluating the performance and operational characteristics of point-of-care tests for the diagnosis of genital gonococcal infections. Sex Transm Infect, 2017 (in press).
371. Jafari, Y, Peeling, RW, Shivkumar, S, Claessens, C, Joseph, L, Pai, NP, Are Treponema pallidum specific rapid and point-of-care tests for syphilis accurate enough for screening in resource limited settings? Evidence from a meta-analysis. PLoS One, 8, 2013, e54695.
372. Tucker, JD, Bu, J, Brown, LB, Yin, YP, Chen, XS, Cohen, MS, Accelerating worldwide syphilis screening through rapid testing: a systematic review. Lancet Infect Dis 10 (2010), 381–386.
373. Mabey, D, Peeling, RW, Ballard, R, et al. Prospective, multi-centre clinic-based evaluation of four rapid diagnostic tests for syphilis. Sex Transm Infect 82:suppl 5 (2006), 13–16.
374. Marks, M, Yin, YP, Chen, XS, et al. Meta-analysis of the performance of a combined treponemal and non-treponemal rapid diagnostic test for syphilis and yaws. Clin Infect Dis 63 (2016), 627–633.
375. Ham, JY, Jung, J, Hwang, BG, et al. Highly sensitive and novel point-of-care system, aQcare Chlamydia TRF kit for detecting Chlamydia trachomatis by using europium (Eu) (III) chelated nanoparticles. Ann Lab Med 35 (2015), 50–56.
376. Samarawickrama, A, Cheserem, E, Graver, M, Wade, J, Alexander, S, Ison, C, Pilot study of use of the BioStar Optical ImmunoAssay GC point-of-care test for diagnosing gonorrhoea in men attending a genitourinary medicine clinic. J Med Microbiol 63 (2014), 1111–1112.
377. Vickerman, P, Watts, C, Alary, M, Mabey, D, Peeling, RW, Sensitivity requirements for the point of care diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in women. Sex Transm Infect 79 (2003), 363–367.
378. Gift, TL, Pate, MS, Hook, EW 3rd, Kassler, WJ, The rapid test paradox: when fewer cases detected lead to more cases treated: a decision analysis of tests for Chlamydia trachomatis. Sex Transm Dis 26 (1999), 232–240.
379. Jafari, Y, Peeling, RW, Shivkumar, S, Claessens, C, Joseph, L, Pai, NP, Are Treponema pallidum specific rapid and point-of-care tests for syphilis accurate enough for screening in resource limited settings? Evidence from a meta-analysis. PLoS One, 8, 2013, e54695.
380. Mabey, DC, Sollis, KA, Kelly, HA, et al. Point-of-care tests to strengthen health systems and save newborn lives: the case of syphilis. PLoS Med, 9, 2012, e1001233.
381. Terris-Prestholt, F, Vickerman, P, Torres-Rueda, S, et al. The cost-effectiveness of 10 antenatal syphilis screening and treatment approaches in Peru, Tanzania, and Zambia. Int J Gynaecol Obstet 130:suppl 1 (2015), S73–S80.
382. Mitchell, KM, Cox, AP, Mabey, D, Tucker, JD, Peeling, RW, Vickerman, P, The impact of syphilis screening among female sex workers in China: a modelling study. PLoS One, 8, 2013, e55622.
383. Peeling, RW, Mabey, D, Celebrating the decline in syphilis in pregnancy: a sobering reminder of what's left to do. Lancet Glob Health 4 (2016), e503–e504.
384. WHO. WHO information note on the use of dual HIV/syphilis rapid diagnostic tests (RDT), 2017, World Health Organization, Geneva.
385. García, PJ, Cárcamo, CP, Chiappe, M, et al. Rapid syphilis tests as catalysts for health systems strengthening: a case study from Peru. PLoS One, 8, 2013, e66905.
386. Smit, PW, Mabey, D, Vlis, TVD, et al. The implementation of an external quality assurance method for point- of- care tests for HIV and syphilis in Tanzania. BMC Infect Dis, 13, 2013, 530.
387. Sabapathy, K, Van den Bergh, R, Fidler, S, Hayes, R, Ford, N, Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med, 9, 2012, e1001351.
388. Fonjungo, PN, Boeras, DI, Zeh, C, Alexander, H, Parekh, BS, Nkengasong, JN, Access and quality of HIV-related point-of-care diagnostic testing in global health programs. Clin Infect Dis 62 (2016), 369–374.
389. Peeling, RW, Mabey, D, Ballard, RC, Introducing new diagnostics into STI control programmes: the importance of programme science. Sex Transm Infect 89 (2013), 115–119.
390. Johnson, AM, Mercer, CH, Cassell, JA, Social determinants, sexual behaviour, and sexual health. Marmot, M, Wilkinson, R, (eds.) Social determinants of health, 2005, Oxford University Press, Oxford, 318–340.
391. Centers for Disease Control and Prevention. Sexually transmitted disease morbidity 1984–2013 archive, CDC WONDER Online Database. http://wonder.cdc.gov/std-v2013-sex.html (accessed Feb 6, 2017).
392. Centers for Disease Control and Prevention. 2015 Sexually Transmitted Diseases surveillance. https://www.cdc.gov/std/stats15/default.htm (accessed May 15, 2017).
393. Feldman, DA, Johnson, TM, Introduction. Feldman, DA, Johnson, TM, (eds.) The social dimensions of AIDS method and theory, 1986, Praeger Publishers, New York.
394. Centers for Disease Control and Prevention. 2014 Sexually Transmitted Diseases Surveillance. Table 1: Sexually transmitted diseases—reported cases and rates of reported cases per 100,000 population, United States. https://www.cdc.gov/std/stats14/tables/1.htm, 1941–2014 (accessed May 15, 2017).
395. Brown, G, Leonard, W, Lyons, A, et al. Stigma, gay men and biomedical prevention: the challenges and opportunities of a rapidly changing HIV prevention landscape. Sex Health, 2016, 10.1071/SH16052 published online Dec 16.
396. Kingsley, LA, Rinaldo, CR Jr, Lyter, DW, Valdiserri, RO, Belle, SH, Ho, M, Sexual transmission efficiency of hepatitis B virus and human immunodeficiency virus among homosexual men. JAMA 264 (1990), 230–234.
397. Public Health England. Syphilis and lymphogranuloma venereum: resurgent sexually transmitted infections in the UK: 2009 report, 2013, Health Protection Agency, London.
398. Quinn, TC, Gay bowel syndrome. The broadened spectrum of nongenital infection. Postgrad Med 76 (1984), 197–198.
399. Hymes, KB, Cheung, T, Greene, JB, et al. Kaposi's sarcoma in homosexual men—a report of eight cases. Lancet 2 (1981), 598–600.
400. Judson, FN, Fear of AIDS and gonorrhea rates in homosexual men. Lancet 2 (1983), 159–160.
401. Rietmeijer, CA, Patnaik, JL, Judson, FN, Douglas, JM Jr, Increases in gonorrhea and sexual risk behaviors among men who have sex with men: a 12-year trend analysis at the Denver Metro Health Clinic. Sex Transm Dis 30 (2003), 562–567.
402. Public Health England. Country and PHE region HIV data tables. https://www.gov.uk/government/statistics/hiv-annual-data-tables, Oct 20, 2015 (accessed May 16, 2017).
403. Health Protection Agency. HIV infection and AIDS in the United Kingdom: monthly report—May 2003. CDR Weekly 13 (2003), 6–23.
404. Health Protection Agency. All new diagnoses made at GUM clinics: 1996–2005. http://webarchive.nationalarchives.gov.uk/20081023132939/http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947397980 (accessed May 16, 2017).
405. Mohammed, H, Mitchell, H, Sile, B, Duffell, S, Nardone, A, Hughes, G, Increase in sexually transmitted infections among men who have sex with men, England, 2014. Emerg Infect Dis 22 (2016), 88–91.
406. Public Health England. Infection report. HIV-STIs. Sexually transmitted infections and chlamydia screening in England, 2015. Health Protect Rep 10 (2016), 6–8.
407. Vernazza, P, Hirschel, B, Bernasconi, E, Flepp, M, HIV- infizierte Menschen ohne andere STD sind unter wirksamer antiretroviraler Therapie sexuell nicht infektiös. Schweiz Arzteztg 89 (2008), 165–169 (in German).
408. McCormack, S, Dunn, DT, Desai, M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 387 (2016), 53–60.
409. Fennema, JS, Cairo, I, Coutinho, RA, Substantial increase in gonorrhea and syphilis among clients of Amsterdam Sexually Transmitted Diseases Clinic. Ned Tijdschr Geneeskd 144 (2000), 602–603 (in Dutch).
410. Malek, R, Mitchell, H, Furegato, M, et al. Contribution of transmission in HIV-positive men who have sex with men to evolving epidemics of sexually transmitted infections in England: an analysis using multiple data sources, 2009–2013. Euro Surveill, 20, 2015, 21093.
411. Klausner, JD, Kent, CK, Wong, W, McCright, J, Katz, MH, The public health response to epidemic syphilis, San Francisco, 1999–2004. Sex Transm Dis 32:suppl (2005), S11–S18.
412. Read, P, Fairley, CK, Chow, EP, Increasing trends of syphilis among men who have sex with men in high income countries. Sex Health 12 (2015), 155–163.
413. Ray, M, Logan, R, Sterne, JA, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 24 (2010), 123–137.
414. Severe, P, Juste, MA, Ambroise, A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 363 (2010), 257–265.
415. Cardo, DM, Culver, DH, Ciesielski, CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 337 (1997), 1485–1490.
416. Quinn, TC, Wawer, MJ, Sewankambo, N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 342 (2000), 921–929.
417. Attia, S, Egger, M, Müller, M, Zwahlen, M, Low, N, Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23 (2009), 1397–1404.
418. Cohen, MS, HIV treatment as prevention and “the Swiss statement”: in for a dime, in for a dollar?. Clin Infect Dis 51 (2010), 1323–1324.
419. Cohen, MS, Smith, MK, Muessig, KE, Hallett, TB, Powers, KA, Kashuba, AD, Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?. Lancet 382 (2013), 1515–1524.
420. Grant, RM, Lama, JR, Anderson, PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363 (2010), 2587–2599.
421. Molina, JM, Capitant, C, Spire, B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 373 (2015), 2237–2246.
422. Blumenthal, J, Haubrich, RH, Will risk compensation accompany pre-exposure prophylaxis for HIV?. Virtual Mentor 16 (2014), 909–915.
423. Richens, J, Imrie, J, Copas, A, Condoms and seat belts: the parallels and the lessons. Lancet 355 (2000), 400–403.
424. Centre for Social Research in Health. Gay Community Periodic Surveys. University of New South Wales. https://csrh.arts.unsw.edu.au/research/publications/gcps/ (accessed May 17, 2016).
425. Chen, YH, Snowden, JM, McFarland, W, Raymond, HF, Pre-exposure prophylaxis (PrEP) use, seroadaptation, and sexual behavior among men who have sex with men, San Francisco, 2004–2014. AIDS Behav 20 (2016), 2791–2797.
426. Paz-Bailey, G, Mendoza, MC, Finlayson, T, et al. Trends in condom use among MSM in the United States: the role of antiretroviral therapy and seroadaptive strategies. AIDS 30 (2016), 1985–1990.
427. Stolte, IG, Dukers, NH, Geskus, RB, Coutinho, RA, de Wit, JB, Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS 18 (2004), 303–309.
428. Crepaz, N, Hart, TA, Marks, G, Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 292 (2004), 224–236.
429. Stolte, IG, de Wit, JB, Kolader, M, Fennema, H, Coutinho, RA, Dukers, NH, Association between 'safer sex fatigue’ and rectal gonorrhea is mediated by unsafe sex with casual partners among HIV-positive homosexual men. Sex Transm Dis 33 (2006), 201–208.
430. Mayer, KH, Mimiaga, MJ, Past as prologue: the refractory and evolving HIV epidemic among men who have sex with men. Clin Infect Dis 52 (2011), 1371–1373.
431. Marcus, U, Schmidt, AJ, Hamouda, O, HIV serosorting among HIV-positive men who have sex with men is associated with increased self-reported incidence of bacterial sexually transmissible infections. Sex Health 8 (2011), 184–193.
432. WHO. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach: December 2014. Supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, 2014, World Health Organization, Geneva.
433. Cresswell, F, Waters, L, Briggs, E, et al. UK guideline for the use of HIV post-exposure prophylaxis following sexual exposure, 2015. Int J STD AIDS 27 (2016), 713–738.
434. Lert, F, Advances in HIV treatment and prevention: should treatment optimism lead to prevention pessimism?. AIDS Care 12 (2000), 745–755.
435. Poynten, IM, Jin, F, Mao, L, et al. Nonoccupational postexposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. AIDS 23 (2009), 1119–1126.
436. Heuker, J, Sonder, GJ, Stolte, I, Geskus, R, van den Hoek, A, High HIV incidence among MSM prescribed postexposure prophylaxis, 2000–2009: indications for ongoing sexual risk behaviour. AIDS 26 (2012), 505–512.
437. Sonder, GJ, van den Hoek, A, Regez, RM, et al. Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000–2004. Sex Transm Dis 34 (2007), 288–293.
438. Granich, RM, Gilks, CF, Dye, C, De Cock, KM, Williams, BG, Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373 (2009), 48–57.
439. Cohen, MS, Chen, YQ, McCauley, M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365 (2011), 493–505.
440. Bacaër, N, Pretorius, C, Auvert, B, An age-structured model for the potential impact of generalized access to antiretrovirals on the South African HIV epidemic. Bull Math Biol 72 (2010), 2180–2198.
441. Iwuji, C, Orne-Gliemann, J, Balestre, E, et al. The impact of universal test and treat on HIV incidence in a rural South African population: ANRS 12249 TasP trial, 2012–2016. http://programme.aids2016.org/Abstract/Abstract/10537, 2016 (accessed May 9, 2017).
442. Iwuji, CC, Orne-Gliemann, J, Larmarange, J, et al. Uptake of home-based HIV testing, linkage to care, and community attitudes about ART in Rural KwaZulu-Natal, South Africa: descriptive results from the first phase of the ANRS 12249 TasP cluster-randomised trial. PLoS Med, 13, 2016, e1002107.
443. Tanser, F, Bärnighausen, T, Grapsa, E, Zaidi, J, Newell, ML, High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 339 (2013), 966–971.
444. Schwarcz, S, Hsu, LC, Scheer, S, Disparities and trends in viral suppression during a transition to a “test and treat” approach to the HIV epidemic, San Francisco, 2008–2012. J Acquir Immune Defic Syndr 70 (2015), 529–537.
445. San Francisco Department of Public Health. San Francisco sexually transmitted disease annual summary. 2005, 2006, San Francisco Department of Public Health, San Francisco.
446. San Francisco Department of Public Health. San Francisco sexually transmitted disease annual summary. 2009, 2010, San Francisco Department of Public Health, San Francisco.
447. San Francisco Department of Public Health. San Francisco sexually transmitted disease annual summary. 2010, 2011, San Francisco Department of Public Health, San Francisco.
448. San Francisco Department of Public Health. San Francisco sexually transmitted disease annual summary. 2014, 2015, San Francisco Department of Public Health, San Francisco.
449. San Francisco Department of Public Health. STDs among men who have sex with men (MSM). San Francisco, 2007–2013, 2014, San Francisco Department of Public Health, San Francisco.
450. Kouyos, RD, Hasse, B, Calmy, A, et al. Increases in condomless sex in the Swiss HIV Cohort Study. Open Forum Infect Dis, 2, 2015, ofv077.
451. Sugarman, J, Bioethical challenges with HIV treatment as prevention. Clin Infect Dis 59:suppl 1 (2014), S32–S34.
452. Fonner, VA, Dalglish, SL, Kennedy, CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 30 (2016), 1973–1983.
453. Grant, RM, Anderson, PL, McMahan, V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 14 (2014), 820–829.
454. Liu, AY, Cohen, SE, Vittinghoff, E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med 176 (2016), 75–84.
455. Volk, JE, Marcus, JL, Phengrasamy, T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis 61 (2015), 1601–1603.
456. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2nd edn., 2016, World Health Organization, Geneva.
457. Centers for Disease Control and Prevention. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf, 2014 (accessed June 2, 2017).
458. Carlo Hojilla, J, Koester, KA, Cohen, SE, et al. Sexual behavior, risk compensation, and HIV prevention strategies among participants in the San Francisco PrEP demonstration project: a qualitative analysis of counseling notes. AIDS Behav 20 (2016), 1461–1469.
459. Newcomb, ME, Mongrella, MC, Weis, B, McMillen, SJ, Mustanski, B, Partner disclosure of PrEP use and undetectable viral load on geosocial networking apps: frequency of disclosure and decisions about condomless sex. J Acquir Immune Defic Syndr 71 (2016), 200–206.
460. Wilson, C, Massive drop in London HIV rates may be due to internet drugs. https://www.newscientist.com/article/2117426-massive-drop-in-london-hiv-rates-may-be-due-to-internet-drugs/, Jan 9, 2017 (accessed May 9, 2017).
461. Phillips, G, Grov, C, Mustanski, B, Engagement in group sex among geosocial networking mobile application-using men who have sex with men. Sex Health 12 (2015), 495–500.
462. Kurth, AE, Celum, C, Baeten, JM, Vermund, SH, Wasserheit, JN, Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep 8 (2011), 62–72.
463. Xiridou, M, Vriend, HJ, Lugner, AK, et al. Modelling the impact of chlamydia screening on the transmission of HIV among men who have sex with men. BMC Infect Dis, 13, 2013, 436.
464. Xiridou, M, Soetens, LC, Koedijk, FD, van der Sande, MA, Wallinga, J, Public health measures to control the spread of antimicrobial resistance in Neisseria gonorrhoeae in men who have sex with men. Epidemiol Infect 143 (2015), 1575–1664.
465. Fingerhuth, SM, Bonhoeffer, S, Low, N, Althaus, CL, Antibiotic-resistant Neisseria gonorrhoeae spread faster with more treatment, not more sexual partners. PLoS Pathog, 12, 2016, e1005611.
466. Gray, RT, Hoare, A, Prestage, GP, Donovan, B, Kaldor, JM, Wilson, DP, Frequent testing of highly sexually active gay men is required to control syphilis. Sex Transm Dis 37 (2010), 298–305.
467. Chow, EPF, Callander, D, Fairley, CK, et al. Increased syphilis testing of men who have sex with men: greater detection of asymptomatic early syphilis and relative reduction in secondary syphilis. Clin Infect Dis, 2017, 10.1093/cid/cix326 published online April 13.
468. Golden, MR, Handsfield, HH, Preexposure prophylaxis to prevent bacterial sexually transmitted infections in men who have sex with men. Sex Transm Dis 42 (2015), 104–106.
469. Bolan, RK, Beymer, MR, Weiss, RE, Flynn, RP, Leibowitz, AA, Klausner, JD, Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis 42 (2015), 98–103.
470. Fairley, CK, Hocking, JS, Zhang, L, Chow, EPF, Transmission of gonorrhoea in men who have sex with men. Emerg Infect Dis 23 (2017), 102–104.
471. Chow, EP, Howden, BP, Walker, S, et al. Antiseptic mouthwash against pharyngeal Neisseria gonorrhoeae: a randomised controlled trial and an in-vitro study. Sex Trans Infect 93 (2017), 88–93.
472. Noori, T, Pharris, A, Meeting report: pre-exposure human immunodeficiency virus prophylaxis in the EU/EEA: challenges and opportunities, Stockholm April 2016. Euro Surveill, 21, 2016.
473. Deckard, DT, Chung, WM, Brooks, JT, et al. Male-to-male sexual transmission of Zika virus—Texas, January 2016. MMWR Morb Mortal Wkly Rep 65 (2016), 372–374.
474. White, PJ, Ward, H, Cassell, JA, Mercer, CH, Garnett, GP, Vicious and virtuous circles in the dynamics of infectious disease and the provision of health care: gonorrhea in Britain as an example. J Infect Dis 192 (2005), 824–836.
475. Hawkes, S, Zaheer, HA, Tawil, O, O'Dwyer, M, Buse, K, Managing research evidence to inform action: influencing HIV policy to protect marginalised populations in Pakistan. Glob Public Health 7 (2012), 482–494.
476. Fairley, CK, Chow, EP, Hocking, JS, Early presentation of symptomatic individuals is critical in controlling sexually transmissible infections. Sex Health 12 (2015), 181–182.
477. Kamb, ML, Fishbein, M, Douglas, JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. JAMA 280 (1998), 1161–1167.
478. Koblin, B, Chesney, M, Coates, T, the EXPLORE Study Team. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet 364 (2004), 41–50.
479. Fairley, CK, Hocking, JS, Sexual health in Indigenous communities. Med J Aust 197 (2012), 597–598.
480. Miller, WC, Ford, CA, Morris, M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 291 (2004), 2229–2236.
481. Wang, SA, Papp, JR, Stamm, WE, Peeling, RW, Martin, DH, Holmes, KK, Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report. J Infect Dis 191 (2005), 917–923.
482. Barbee, LA, Dombrowski, JC, Kerani, R, Golden, MR, Effect of nucleic acid amplification testing on detection of extragenital gonorrhea and chlamydial infections in men who have sex with men sexually transmitted disease clinic patients. Sex Transm Dis 41 (2014), 168–172.
483. Hui, B, Fairley, CK, Chen, M, et al. Oral and anal sex are key to sustaining gonorrhoea at endemic levels in MSM populations: a mathematical model. Sex Transm Infect 91 (2015), 365–369.
484. Zhang L, Regan D, Gambhir M, et al. Neisseria gonorrhoeae transmission among men who have sex with men: an anatomical site-specific mathematical model evaluating the potential preventive impact of mouthwash. Sex Transm Dis (in press).
485. Chow, EP, Cornelisse, VJ, Read, TR, et al. Saliva use as a lubricant for anal sex is a risk factor for rectal gonorrhoea among men who have sex with men, a new public health message: a cross-sectional survey. Sex Transm Infect, 2016, 10.1136/sextrans-2015-052502 published online March 3.
486. Chow, EP, Machalek, DA, Tabrizi, SN, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis 17 (2017), 68–77.